News
MAIA
3.280
+4.13%
0.130
MAIA Biotechnology Announces Independent Director Ms. Adelina Louie Ngar Yee Made An Individual Purchase Of 19,665 Shares, And Warrants For 19,665 Shares Of Common Stock
Original seed investor has remained top MAIA stockholder. Adelina Louie Ngar Yee made an individual purchase of 19,665 shares of MAIA's common stock. MAIA is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer.
Benzinga · 5d ago
MAIA Biotechnology Shares Hit 52-Week High After Director Stock Purchase
MAIA Biotechnology shares hit their 52-week high. Independent director Stan Smith made an individual purchase of 147,000 shares. The stock is up 12% to $3.30 in recent trading. The company's recent private placement of shares raised $1 million.
Dow Jones · 5d ago
Monday 4/29 Insider Buying Report: AYI, MAIA
NASDAQ · 5d ago
Weekly Report: what happened at MAIA last week (0422-0426)?
Weekly Report · 6d ago
MAIA Biotechnology announces $1M private placement
MAIA Biotechnology, Inc. Announces $1M private placement. The company intends to use the net proceeds from the offering to fund research and development activities. The private placement is expected to close on or about April 25. MAIA biotechnology announced $1m private placement of shares of stock.
Seeking Alpha · 04/23 13:02
MAIA BIOTECHNOLOGY ANNOUNCES $1.00 MILLION PRIVATE PLACEMENT
Reuters · 04/23 12:51
Weekly Report: what happened at MAIA last week (0415-0419)?
Weekly Report · 04/22 12:07
Weekly Report: what happened at MAIA last week (0408-0412)?
Weekly Report · 04/15 11:57
Weekly Report: what happened at MAIA last week (0401-0405)?
Weekly Report · 04/08 12:03
MAIA Biotechnology to Present at Two Investor Conferences in April 2024
MAIA Biotechnology, Inc. Is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Vlad Vitoc, M.D. Will present at two investor conferences during the month of April. The company's lead candidate is THIO, a potential first-in-class cancer telomere targeting agent.
Barchart · 04/05 07:01
MAIA Biotechnology Boosts CEO Jeffrey Himmelreich’s Salary
TipRanks · 04/02 20:22
Weekly Report: what happened at MAIA last week (0325-0329)?
Weekly Report · 04/01 12:00
MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero
MAIA Biotechnology, Inc. Is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Independent directors Cristian Luput and Ramiro Guerrero made purchases of shares of common stock as part of the Company’s recent private placement. MAIA is a targeted therapy, immuno-oncology company focused on the development of potential first-in-class cancer drugs.
Barchart · 03/28 14:00
GOEV, NBSE and FLGC among pre-market losers
GOEV, NBSE and FLGC among pre-market losers. NeuBase Therapeutics (NBSE) -58%. AppTech Payments Corp (APCX) announces proposed underwritten public offering. Bluebird bio (BLUE) reports Q4 results.
Seeking Alpha · 03/26 12:15
MAIA Biotechnology looks to raise $1.33M through a private placement
MAIA Biotechnology looks to raise $1.33M through a private placement. Shares in the company down 7.45% in pre-market trade. The company has entered into definitive agreements to sell 578.6K shares at $2.29 each.
Seeking Alpha · 03/26 12:06
MAIA Biotechnology Announces $1.33M Private Placement of 0.6M Shares at $2.295/Share
MAIA Biotechnology, Inc. Is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The company has entered into definitive agreements for the purchase and sale of 578,643 shares of common stock to accredited investors. The private placement is expected to close in 2024. The gross proceeds from the offering are expected to be approximately $1.33 million.
Benzinga · 03/26 12:05
*MAIA Biotechnology Announces $1.33M Private Placement
Dow Jones · 03/26 12:03
BUZZ-U.S. STOCKS ON THE MOVE-Super Micro, Micron Technology, Navios Maritime
Dow Jones Industrial Average was down 0.36% on Monday. Top three S&P 500 percentage gainers: Super Micro Computer, Micron Technology, Navios Maritime. Wall Street's main indexes eased at the start of the holiday-shortened week. Advancing chip stocks kept losses on the tech-heavy Nasdaq in check.
Reuters · 03/25 17:56
CGC, CYTO and IDN are among mid-day movers
On the Move CGC, CYTO and IDN are among mid-day movers. Landos Biopharma and MoneyHero are among the biggest gainers. Australian Oilseeds and Aehr Test Systems are among those that lost ground in the last 24 hours.
Seeking Alpha · 03/25 17:25
BUZZ-U.S. STOCKS ON THE MOVE-Landos Biopharma, Foot Locker, US energy sector
Wall Street's main indexes open lower on Monday. Dow Jones Industrial Average was down 0.26% at 39,373.11. Boeing gained after the planemaker said its CEO would be stepping down. Landos Biopharma, Foot Locker, US energy sector rise.
Reuters · 03/25 15:58
More
Webull provides a variety of real-time MAIA stock news. You can receive the latest news about MAIA Biotechnology Inc. through multiple platforms. This information may help you make smarter investment decisions.
About MAIA
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.